All In Biotech

Drug Trial Radar · NCT03375203

A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder

A Multicenter, Double-Blind, Randomized, Parallel-Group, Active- and Placebo-Controlled Polysomnography Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Subjects With Insomnia Disorder

Last checked: Nov 20, 2026Latest source record: Apr 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 365 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

365

Actual

Start

Nov 23, 2017

Primary completion

Apr 3, 2019

Study completion Apr 3, 2019

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Dec 15, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this 2 month phase 2b study is to investigate the dose response of 3 doses of JNJ-42847922 (Seltorexant) (5,10 and 20 mg) compared to placebo and zolpidem on sleep onset and maintenance and to further document safety and tolerability of JNJ-42847922 (Seltorexant) upon multiple (14 days) dose administration in participants with insomnia disorder.

Conditions

  • Insomnia Disorders

Interventions

  • PlaceboDrug

    Matching placebo will be administered once daily based upon dosing group.

  • JNJ-42847922, 5 mgDrug

    JNJ-42847922 will be administered as 5 mg (2\*2.5 mg capsule) oral capsules once daily.

  • JNJ-42847922, 10 mgDrug

    JNJ-42847922 will be administered as 10 mg oral capsule once daily.

  • JNJ-42847922, 20 mgDrug

    JNJ-42847922 will be administered as 20 mg oral capsule once daily.

  • ZolpidemDrug

    Zolpidem will be administered as 5 mg or 10 mg (2\*5mg capsule) oral capsule once daily based upon the local labeling information.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Latency to Persistent Sleep (LPS) as Measured by Polysomnography (PSG) on Night 1Time frame: Baseline and Night 1

Locations

56 sites in 6 countries. Site status is shown where the registry gives one.

  • Preferred Research Partners

    Little Rock, Arkansas

  • Woodland Research Northwest

    Rogers, Arkansas

  • California Research Trials DBA Orange Country Research Institute

    Anaheim, California

  • Excell Research Inc

    Oceanside, California

  • Artemis Institute for Clinical Research

    San Diego, California

  • Empire Clinical Research, LLC

    Upland, California

  • St. Francis Medical Institute

    Clearwater, Florida

  • Avail Clinical Research, LLC

    DeLand, Florida

  • Sarkis Clinical Trials

    Lake City, Florida

  • Innovative Clinical Research Inc

    Lauderhill, Florida

  • Suncoast Research Group

    Miami, Florida

  • Renstar Medical Research

    Ocala, Florida

  • Palm Beach Research Center

    West Palm Beach, Florida

  • Atlanta Center for Medical Research

    Atlanta, Georgia

  • NeuroTrials Research, Inc.

    Atlanta, Georgia

  • Chicago Research Center

    Chicago, Illinois

  • Centennial Medical Group

    Elkridge, Maryland

  • Clinical Research Center of Nevada

    Las Vegas, Nevada

  • Gastonia Medical Specialty Clinic

    Gastonia, North Carolina

  • Clinical Research of Lake Norman

    Mooresville, North Carolina

  • CTI Clinical Trial and Consulting Services

    Cincinnati, Ohio

  • Lynn Health Science Institute

    Oklahoma City, Oklahoma

  • Clinical Research of Charleston

    Mt. Pleasant, South Carolina

  • FutureSearch Trials of Neurology, LP

    Austin, Texas

  • Anima

    Alken, Belgium

  • Cliniques Universitaires Saint Luc

    Brussels, Belgium

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • UZ Leuven Gasthuisberg

    Leuven, Belgium

  • Universiteit Antwerpen

    Wilrijk, Belgium

  • CHU de Grenoble Hopital Albert Michallon

    Isere, France

  • Hopital de La Croix Rousse

    Lyon, France

  • Hôpital Hôtel Dieu - Paris

    Paris, France

  • Centre Hospitalier Specialisé de Rouffach

    Rouffach, France

  • Advanced Sleep Research GmbH

    Berlin, Germany

  • Emovis GmbH

    Berlin, Germany

  • Synexus Clinical Research GmbH

    Frankfurt, Germany

  • CTC North GmbH & Co. KG

    Hamburg, Germany

  • Synexus Clinical Research GmbH

    Sachsen, Germany

  • Somni Bene GmbH

    Schwerin, Germany

  • Klinische Forschung Schwerin GmbH

    Schwerin, Germany

Showing 40 of 56 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.